$197.90 Million in Sales Expected for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) This Quarter

Brokerages expect Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to announce sales of $197.90 million for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Alnylam Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $179.68 million and the highest estimate coming in at $221.00 million. Alnylam Pharmaceuticals posted sales of $103.96 million in the same quarter last year, which would indicate a positive year over year growth rate of 90.4%. The company is expected to issue its next quarterly earnings report on Thursday, August 5th.

According to Zacks, analysts expect that Alnylam Pharmaceuticals will report full-year sales of $840.05 million for the current fiscal year, with estimates ranging from $799.43 million to $914.70 million. For the next fiscal year, analysts forecast that the firm will report sales of $1.30 billion, with estimates ranging from $1.06 billion to $1.50 billion. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Wednesday, April 28th. The biopharmaceutical company reported ($1.71) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.75) by $0.04. Alnylam Pharmaceuticals had a negative net margin of 222.19% and a negative return on equity of 65.96%. During the same quarter in the previous year, the firm earned ($1.62) EPS.

Several research firms recently issued reports on ALNY. BMO Capital Markets lowered shares of Alnylam Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $185.00 price target on the stock. in a research report on Monday, January 25th. Royal Bank of Canada reiterated a “hold” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, February 14th. Guggenheim reiterated a “neutral” rating and set a $162.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, March 1st. Morgan Stanley reduced their price target on shares of Alnylam Pharmaceuticals from $206.00 to $205.00 and set an “overweight” rating on the stock in a research report on Friday. Finally, Needham & Company LLC restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, April 20th. Nine equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $166.75.

In other news, insider Akshay Vaishnaw sold 2,732 shares of the firm’s stock in a transaction on Wednesday, April 21st. The shares were sold at an average price of $136.95, for a total transaction of $374,147.40. Following the completion of the transaction, the insider now owns 22,908 shares of the company’s stock, valued at $3,137,250.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.50% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. State Board of Administration of Florida Retirement System raised its stake in Alnylam Pharmaceuticals by 6.4% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 160,226 shares of the biopharmaceutical company’s stock worth $20,825,000 after buying an additional 9,617 shares during the last quarter. Aperio Group LLC raised its stake in Alnylam Pharmaceuticals by 5.2% during the fourth quarter. Aperio Group LLC now owns 44,387 shares of the biopharmaceutical company’s stock worth $5,769,000 after buying an additional 2,192 shares during the last quarter. NN Investment Partners Holdings N.V. raised its stake in Alnylam Pharmaceuticals by 32.8% during the fourth quarter. NN Investment Partners Holdings N.V. now owns 16,613 shares of the biopharmaceutical company’s stock worth $2,159,000 after buying an additional 4,099 shares during the last quarter. DnB Asset Management AS raised its stake in Alnylam Pharmaceuticals by 48.4% during the first quarter. DnB Asset Management AS now owns 23,386 shares of the biopharmaceutical company’s stock worth $3,302,000 after buying an additional 7,629 shares during the last quarter. Finally, Rhenman & Partners Asset Management AB raised its stake in Alnylam Pharmaceuticals by 11.7% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 111,700 shares of the biopharmaceutical company’s stock worth $14,518,000 after buying an additional 11,700 shares during the last quarter. 92.35% of the stock is owned by institutional investors and hedge funds.

Shares of ALNY traded down $5.30 during mid-day trading on Monday, hitting $135.34. 551,974 shares of the company’s stock were exchanged, compared to its average volume of 653,694. The firm has a market cap of $15.88 billion, a price-to-earnings ratio of -17.28 and a beta of 1.47. The stock’s 50-day simple moving average is $139.69 and its 200-day simple moving average is $141.57. Alnylam Pharmaceuticals has a 52 week low of $119.29 and a 52 week high of $178.41.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Recommended Story: Stocks at 52 Week High

Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.